Brief: Instil Bio Says Due To Workforce Reduction, Co No Longer Expects To Report Clinical Data From ITIL-306-202 Clinical Trial In 2024
16/01/2024 22:37
Jan 16 (Reuters) - Instil Bio Inc TIL.O :
* INSTIL BIO INC - AS A RESULT OF WORKFORCE REDUCTION, CO
NO
LONGER EXPECTS TO REPORT CLINICAL DATA FROM ITIL-306-202
CLINICAL TRIAL IN 2024
* INSTIL BIO INC - IN CONNECTION WITH RESTRUCTURING PLAN
ESTIMATES
THAT IT WILL INCUR AGGREGATE RESTRUCTURING COSTS OF UP TO $6.1
MILLION
Further company coverage: TIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Instil Bio
See all newsInstil Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Instil Bio Q2 net loss narrows on lower R&D spending, restructuring charges
Brief: Instil Bio Q2 Basic EPS USD -0.63
Instil Bio, Inc. expected to post a loss of 43 cents a share - Earnings Preview
Instil Bio Q1 net loss narrows on lower R&D expenses